Efficacy and safety of reduced thromboprophylaxis with low molecular weight heparin for hepatocellular carcinoma after conversion therapy
Abstract Background Tyrosine kinase inhibitors (TKIs) impairs factor Xa (FXa)-mediated coagulation. This study aims to assess the safety and feasibility of reduced thromboprophylaxis with low molecular weight heparin (LMWH) for hepatocellular carcinoma (HCC) converted by Lenvatinib treatment. Method...
Saved in:
| Main Authors: | Xu Zhang, Zhiguo Ai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-04208-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
by: Hang Li, et al.
Published: (2025-01-01) -
Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China
by: Ye Q, et al.
Published: (2025-08-01) -
Adding dendritic cell-immunotherapy for post-transplant hepatocellular carcinoma recurrence
by: Wei-Chen Lee, et al.
Published: (2025-08-01) -
Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study
by: Zhao-dan Ye, et al.
Published: (2025-07-01) -
Exploring 1,3,4-oxadiazole derivatives for hepatocellular carcinoma: synthesis, and bioactivity evaluation
by: Mohini Patidar, et al.
Published: (2025-04-01)